New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - meglumine amidotrizoate 660 mg/ml (formed from meglumine and amidotrizoic acid); sodium amidotrizoate 100 mg/ml (formed from sodium hydroxide and amidotrizoic acid) - solution for infusion - 76 % - active: meglumine amidotrizoate 660 mg/ml (formed from meglumine and amidotrizoic acid) sodium amidotrizoate 100 mg/ml (formed from sodium hydroxide and amidotrizoic acid) excipient: sodium calcium edetate water for injection - intravenous and retrograde urography. also for all angiographic examinations as well as for amniography, arthrography, intraoperative cholangiography, endoscopic retrograde cholangiopancreatography (ercp), sialography, fistulography, hysterosalpingography, splenoportography, vesiculography and others. urografin is not to be used for myelography, ventriculography or cisternography, since it is likely to provoke neurotoxic symptoms in these examinations.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - meglumine amidotrizoate 660 mg/ml (formed from melgumine and amidotrizoic acid); sodium amidotrizoate 100 mg/ml (formed from sodium hydroxide and amidotrizoic acid) - oral solution - active: meglumine amidotrizoate 660 mg/ml (formed from melgumine and amidotrizoic acid) sodium amidotrizoate 100 mg/ml (formed from sodium hydroxide and amidotrizoic acid) excipient: anise oil disodium edetate polysorbate 80 purified water saccharin sodium

Malta - English - Medicines Authority

bayer plc - meglumine amidotrizoate; sodium amidotrizoate - gastroenteral solution - meglumine amidotrizoate 660 mg/ml; sodium amidotrizoate 100 mg/ml - contrast media

Ireland - English - HPRA (Health Products Regulatory Authority)

bayer limited - sodium amidotrizoate; amidotrizoate meglumine; amidotrizoic acid; meglumine - oral/rectal solution - 660 and 100 milligram(s)/millilitre - watersoluble, hepatotropic x-ray contrast media; sodium iopodate

Malta - English - Medicines Authority

bayer hellas s.a 6-8 agisilaou street 151 23 marousi attiki, , greece - meglumine amidotrizoate, sodium amidotrizoate - gastroenteral solution - sodium amidotrizoate 10 g/100ml meglumine amidotrizoate 66 g/100ml - contrast media

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bayer plc - meglumine amidotrizoate; sodium amidotrizoate - solution for injection - 260mg/1ml ; 40mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bayer plc - sodium amidotrizoate; meglumine amidotrizoate - solution for injection - 40mg/1ml ; 260mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bayer plc - sodium amidotrizoate; meglumine amidotrizoate - oral solution - 100mg/1ml ; 660mg/1ml

Israel - English - Ministry of Health

promedico ltd - meglumine ioxitalamate - solution for injection - meglumine ioxitalamate 66.03 g / 100 ml - meglumine antimonate - meglumine antimonate - for urograph, selective angiography, peripheral angiography, arthrography, hysterosalpingography and digestive exploration.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - meglumine amidotrizoate 260 mg/ml (formed from melgumine and amidotrizoic acid); sodium amidotrizoate 40 mg/ml (formed from sodium hydroxide and amidotrizoic acid) - solution for infusion - 30 % - active: meglumine amidotrizoate 260 mg/ml (formed from melgumine and amidotrizoic acid) sodium amidotrizoate 40 mg/ml (formed from sodium hydroxide and amidotrizoic acid) excipient: sodium calcium edetate water for injection